A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment.
Suneil Jain(Queen's University Belfast), David Waugh(University of South Australia), Viktor Berge(Oslo University Hospital), C. Lyons(Cork University Hospital), Stephen McQuaid(Queen's University Belfast), Joe M. O’Sullivan(San Antonio College), Jacqueline A. James(Queen's University Belfast), Seán O. Hynes(University Hospital Galway), Steven M. Walker(Almac (United Kingdom)), Paul Harkin, Andrena McCavigan(Almac (United Kingdom)), Brendan Pang(National University Cancer Institute, Singapore), Gemma E. Logan(Almac (United Kingdom)), Richard D. Kennedy(Queen's University Belfast), David E. Neal(University of Cambridge), Laura A. Knight(Almac (United Kingdom)), C.J. Davidson(Queen's University Belfast), D. Mitchell(University of Ulster), Declan O’Rourke(University of Ulster), Hardev S. Pandha(University of Surrey)
Cited by 0
Related Papers
QuPath: Open source software for digital pathology image analysis
|Scientific Reports|2017|8.9k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Multiple newly identified loci associated with prostate cancer susceptibility
|Nature Genetics|2008|850